Valeant Could Be On the Cusp of Another Surge Higher

The Canadian drugmaker landed a relatively rare bullish brokerage note

Managing Editor
Jan 5, 2018 at 9:19 AM
facebook twitter linkedin

Drug stock Valeant Pharmaceuticals International Inc (NYSE:VRX) is continuing its climb higher, after brokerage firm TD Securities raised its price target to $27 from $20 earlier. The firm is in the minority with its "buy" rating on VRX; currently, the stock sports just four "buy" or better ratings, compared to 10 "holds" and five "sells."  

VRX shares are up 1.3% at $23.36 in electronic trading, not far from their Jan. 3 annual high of $23.47. From a broader perspective, VRX has rallied more than 140% in the past nine months alone.

What's more, the security also sports a Schaeffer's Volatility Index (SVI) of 49%, which ranks in just the 12th percentile of its annual range. According to Schaeffer's Senior Quantitative Analyst Rocky White, the last (and only other) time VRX was trading near a 52-week high with an SVI this low, the security went on to rally nearly 32% over the next month.

In the options pits, data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows VRX's 10-day call/put volume ratio at an extreme 5.93, which ranks in the 100th percentile of its annual range. This suggests that calls have been purchased over puts at an annual-high pace.

However, some of those calls may have been bought as hedges. Short interest on VRX ramped up by 7% in the most recent reporting period, and now represents 11.1% of the equity's float. Given the stock's strongly bullish momentum of late, it's no surprise that these short sellers might be looking to limit losses via a call option hedge.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners